IMYX 5
Alternative Names: IMYX-5Latest Information Update: 17 Feb 2023
At a glance
- Originator Immunyx
- Class Antineoplastics
- Mechanism of Action Neutrophil modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Feb 2023 Early research in Cancer in USA (unspecified route) (Immunyx pipeline; January 2023)
- 02 Feb 2023 Immunyx plans pre-IND studies for Cancer in Q4 2023 (Immunyx pipeline; January 2023)